**3. Related donor cord blood transplantation for thalassemia**

In 1995, the first CBT for thalassemia was reported, using a HLA-identical sibling donor cord blood for a two-and-half-year old [36]. Busulfan/cyclophosphamide conditioning regimen and cyclosporine/methotrexate GvHD prophylaxis were used. The TNC dose was 3.9 × 107 /kg, and the thawed product was not washed and was directly infused on June 12, 1993. Neutrophil and platelet engraftment were achieved by day +23 and day +27, respectively. The patient experienced no GvHD, and the patient was alive and transfusion independent 48 months after transplantation. The various studies using related donor CBT for thalassemia are summarized in **Table 1** [23–25, 28–30, 36, 56, 59, 63–68].



Various other approaches have been tried to improve the outcome of CBT for thalassemia, ranging from preference for superior HLA matches [4, 6, 26, 31, 34, 37, 51–53], usage of related HLA-identical donors [23–25], directed sibling cord blood bank efforts [30, 56], consideration of non-inherited maternal antigen (NIMA) matches [57], preference for IV busulfan over oral formulations [6, 58], the addition of thiotepa to the conditioning regimen [24, 25], reduced intensity conditioning regimens [3, 59, 60], the avoidance of methotrexate in the prophylaxis regimen [23–25], third-party MSC co-infusion [59], and intrabone direct injection of cord blood

In 1995, the first CBT for thalassemia was reported, using a HLA-identical sibling donor cord blood for a two-and-half-year old [36]. Busulfan/cyclophosphamide conditioning regimen and

the thawed product was not washed and was directly infused on June 12, 1993. Neutrophil and platelet engraftment were achieved by day +23 and day +27, respectively. The patient experienced no GvHD, and the patient was alive and transfusion independent 48 months after transplantation. The various studies using related donor CBT for thalassemia are summar-

**[36] [64] [28] [65] [23] [29] SDCB [30, 56] [24] [25]**

baby donor's PB

5.5/ 3.5–10

6 1 2

6.6/ 3.4–12.7 (1) 14 Thal 4/14 + PB (2) 7 Thal

(1) NA 5.9/ 2–11

(1) NA (2) 4.7/ 0.8–7.6

5/9 (1) Thal 12/14 (2) Thal 6/6 with

engraftment

1 33 9; 2 + 

1–20

41 3

1.2–13 PF 4.0/ 1.2–10 PT

6.1 5.1/

1/1 ANC 89% D+23 (12–60)

0 1 /kg, and

27 66

5.9/ 2–20

100% 0/0 0/0

3.9 1.5–14

ANC 90 ± 4%; D +23 Plt

6 0.8–18

0 0

3.3 1.5–6

100% (27/27) 100% (27/27)

(1) 14 (2) 7 100%

cyclosporine/methotrexate GvHD prophylaxis were used. The TNC dose was 3.9 × 107

**3. Related donor cord blood transplantation for thalassemia**

186 Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine

ized in **Table 1** [23–25, 28–30, 36, 56, 59, 63–68].

5 CB + BM

2/1.2/2.5 Combined 3.2/2.8/3.7

5/5 CB + BM

2.5 2.2/3.8 4, 13, 15 3 5

128 0

2/2 1/3CB

3.9 6.2/11.4 CB

ANC 1/1; D+23 Plt
